8-MOP Drug Patent Profile

« Back to Dashboard

When do 8-mop patents expire, and when can generic versions of 8-mop launch?

8-mop is a drug marketed by Valeant Pharm Intl and is included in one NDA.

The generic ingredient in 8-MOP is methoxsalen. One supplier is listed for this compound. Additional details are available on the methoxsalen profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for 8-mop

A generic version of 8-MOP was approved as methoxsalen by ONESOURCE on June 5^th, 2014.

Summary for 8-MOP

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for 8-MOP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Valeant Pharm Intl	8-MOP	methoxsalen	CAPSULE;ORAL	009048-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Last updated: February 3, 2026

What Is 8-MOP?

8-Methoxypsoralen (8-MOP) is a naturally occurring furanocoumarin compound used primarily in photochemotherapy treatments. Its primary medical applications include psoriasis, vitiligo, and other skin conditions, often in conjunction with UVA light therapy (PUVA therapy). It has been in medical use for decades, with established protocols and regulatory approvals in various countries.

Market Overview and Growth Dynamics

Current Market Status

• The global pharmaceutical market for psoralen derivatives, including 8-MOP, was valued at approximately $XX million in 2022.
• It is primarily utilized in dermatology, with regional markets in Europe and North America leading due to higher adoption rates.
• In 2022, the PUVA therapy segment witnessed steady growth, driven by psoriasis prevalence and expanding dermatologist awareness.

Market Drivers

• Increasing psoriasis prevalence (estimated at 125 million globally [1]).
• Rising adoption of photochemotherapy in dermatological treatment protocols.
• Regulatory approval for 8-MOP-based therapies in multiple jurisdictions.
• Initiatives to optimize PUVA therapy protocols, improving safety profile.

Market Challenges

• Competition from biologic therapies offering targeted action.
• Concerns over long-term UVA exposure risks.
• Limited patent protection, affecting pricing power.

Future Growth Projections

• Expected compound annual growth rate (CAGR) of 3-5% over the next five years.
• Market expansion possible through new indications and formulations.
• Potential entry of biosimilar or generic versions impacting pricing.

Regulatory and Patent Fundamentals

Regulatory Landscape

• In the U.S., 8-MOP is categorized under compounded preparations rather than approved drugs, limiting commercial-scale manufacturing.
• European Medicines Agency (EMA) has recognized 8-MOP for PUVA treatments, with several approvals for formulations.
• Other markets (Japan, Australia) have similar recognition pathways.

Patent and Intellectual Property

• 8-MOP, being a naturally occurring compound, faces limited patent protection.
• Companies develop formulations, delivery devices, and combination therapies to extend patent lives.
• No recent patents filed specifically on 8-MOP; innovation tends toward proprietary formulations or administration methods.

Patent Expiry and Biosimilar Threats

• Key patents related to formulations or delivery methods expired or are nearing expiration.
• Biosimilar and generic competition expected to increase, leading to price pressures.

Investment and Commercialization Considerations

Profitability Factors

• Margins are constrained by generic competition and low-price sensitivity.
• Specialty formulations and combination therapies may offer higher margins.
• Licensing agreements with regional partners expand commercialization potential.

R&D and Pipeline Status

• Limited ongoing R&D for novel derivatives; most investment focused on optimizing current formulations.
• Potential areas include targeted delivery systems, combined drug regimens, or novel phototherapy protocols.

Strategic Risks

• Regulatory ambiguities in certain markets.
• Competitive landscape dominated by biologics and newer phototherapeutic agents.
• Public perception issues related to UVA exposure risks.

Fundamentals Analysis Summary

Aspect	Observation
Market Size	$XX million in 2022
Growth Rate	3-5% CAGR expected over five years
Patent Protection	Limited; mostly on formulations/delivery methods
Regulatory Status	Approved in Europe, limited in U.S.
Competitive Environment	Moderate; biosimilars and generics emerging
R&D Focus	Formulation improvements; limited novel derivatives

Key Takeaways

• The market for 8-MOP remains steady with slow growth driven by dermatology applications.
• Patent protections are diminishing, increasing competition.
• Most value comes from proprietary formulations and delivery innovations.
• Regulatory landscape varies, complicating global commercialization.
• R&D investment prioritizes delivery systems rather than new chemical entities.

FAQs

1. What are the primary medical applications of 8-MOP?
   Psoriasis, vitiligo, and other skin conditions treated with PUVA therapy.

2. How does patent expiration affect the market?
   Loss of patent exclusivity leads to increased generic entry and price competition.

3. Are there emerging alternatives to 8-MOP in phototherapy?
   Yes. Biologic agents targeting specific immune pathways are gaining popularity.

4. What regions present the best opportunities for growth?
   Europe and North America, where PUVA therapy remains more established.

5. What are the main R&D priorities for companies involved with 8-MOP?
   Improving delivery systems, combining with other therapies, and expanding indications.

---

Citations

[1] Global psoriasis prevalence data, National Psoriasis Foundation.